New DNA evidence says significant chunks of humanity may carry genes from a few powerful men, including Genghis Khan.» Read More
Following is Cramer's homework. And he's concerned about a few of the stocks he's just researched.
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
Mark Lehmann, JMP Securities president, provides investment strategies that include a biotech company with a promising drug to fight a rare form of Leukemia.
Road trip! Road trip! In the second stop, CNBC's Brian Sullivan reports on the biotech boom in San Diego.
San Diego Mayor Bob Filner (D) discusses the growing sectors in the city, rising home prices, and the burgeoning biotech industry.
CNBC's Jane Wells reports on business in San Diego, how the city has come back from the brink of bankruptcy, and the diversity of the economy. Just the same, taxes are among the highest in the country.
San Diego has the 2nd largest biotech industry in the U.S. CNBC's Brian Sullivan is there to check it out.
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
It is the 95th consecutive trading session in which Apple shares trade below its 50-day moving average, reports CNBC's Seema Mody.
CNBC's Seema Mody reports BlackBerry is up today after reports that BBerry 10 is selling faster than expected.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
Biotech stocks are outperforming the major indices, and are up 3 percent over the past week. CNBC's Seema Mody is tracking which stocks are trending on Twitter.
Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.
Charles River Laboratories CEO James Foster discusses competition in the drug market, drug patents and where his business is headed in 2013.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
"As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
CNBC's Seema Mody reports the pharmaceutical and biotech sectors rally as the JPMorgan conference kicks off its second day.
Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.
The U.S. has given national security clearance to the purchase of an American DNA sequencing company by a Chinese firm, The New York Times reports.